How Do We Identify HER2+ Gastric Cancer?

Please Note: Credit Is No Longer Available


The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.

Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo.


Presented by Creative Educational Concepts, Inc.         

Target Audience

GI oncologists, medical oncologists, molecular pathologists, and other members of the GI oncology healthcare team involved in the diagnosis and treatment of HER2+ gastric cancer.

Learning Objectives

Consider expert guidance and formal practice guidelines to assess HER2 in metastatic gastrointestinal cancers.

Additional Information

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation
Course opens: 
Course expires: 

David H. Ilson, MD, PhD 
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY



Dr. Ilson completed undergraduate training at the University of Connecticut. He entered an MD, PhD combined degree program at New York University and received a Master’s degree and PhD in Basic Science and an MD from New York University. He completed his internship and residency in Internal Medicine at Bellevue Hospital at NYU in New York. He then moved to Memorial Sloan-Kettering Cancer Center and completed a fellowship in Medical Oncology and Hematology, including a third-year fellowship as the Brian Piccolo research fellow.

Dr. Ilson joined the staff at MSKCC in 1992, becoming a member of the GI Oncology Service in the Department of Medicine. He was a recipient of an American Cancer Society Career Development Award. Dr. Ilson is now an attending physician and member at Memorial Hospital and is Professor of Medicine at Weill-Cornell Medical College. His area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. Dr. Ilson is a nationally recognized authority in the treatment of gastrointestinal cancer. His research has focused on the study of new agents in advanced esophageal cancer and on the evaluation of novel agents in combined modality therapy programs in locally advanced disease. Dr. Ilson sits on the GI committees of Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG) as well as the Upper GI Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN). He is chairman on the Intergroup Esophageal and Gastric Cancer Task Force Committee. Dr. Ilson currently chairs or co-chairs several national clinical trials in esophageal cancer. Dr. Ilson has been writing for NEJM Journal Watch Oncology and Hematology since 2006.


Michael F. Press, MD, PhD
Harold E. Lee Chair in Cancer Research
Professor of Pathology
Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, CA


Dr. Press is a Professor in the Department of Pathology and holds the Harold E. Lee Chair in Cancer Research at the University of Southern California’s Norris Comprehensive Cancer Center. He is a board-certified pathologist, directs the USC Breast Cancer Analysis Laboratory as well as the Central Laboratory for the Translational Research In Oncology (TRIO)/Cancer International Research Group (CIRG), and is Leader of the USC Clinical Laboratories.

The research interest of the Press laboratory is in molecular alterations of cancers, especially those that have the potential to be important in either diagnostic or therapeutic decision-making for patient management.  The laboratory has a long-standing record of activity investigating HER2 gene amplification and overexpression with assessment of this alteration as a target for therapy in breast, ovarian, endometrial, salivary gland and gastric cancers, as well as others.  His research has been continuously funded by research grants for more than 35 years. He is the author or co-author of more than 250 peer-reviewed publications. The most prominent area of activity for his laboratory has been in the study of the human epidermal growth factor receptor type 2 (HER2) in breast and other cancers. He published his first paper in this area in 1989 and his laboratory is still actively contributing to this area as well as to the conduct of clinical trials evaluating HER2 as a target for therapy.  The Press laboratory is also investigating the potential for cell cycle regulatory proteins, especially PLK4 and TTK / MPS1, as targets for treatment with small molecule inhibitors. 

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

David H. Ilson, MD, PhD—has disclosed that he is a consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, and Roche.
Susan H. Gitzinger, PharmD, MPA—has no relevant financial relationships to disclose in relation to the content of this activity.

David H. Ilson, MD, PhD—has disclosed that he is a consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, and Roche.
Michael F. Press, MD, PhD—has disclosed that he is a consultant for AstraZeneca, Biocartis SA, Cepheid, Eli Lilly & Company, Merck, Puma Biotechnology, and Zymeworks Inc. He also receives other financial or material support from TORL BioTherapeutics, LLC.

Peer Reviewers:
Allison Butts, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Efrat Dotan, MD—has disclosed that she is a consultant for Basilea and QED. She receives grant/research support from AstraZeneca, Incyte, Ipsen, Lilly, Medimmune, and SDP oncology.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this web-based enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a post-test, evaluation, and credit request, statements of credit for physicians will be issued automatically.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation
Please login or register to take this course.